Med BioGene Responds to Frivolous and Vexatious Lawsuit


VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 14, 2011) - Med BioGene Inc. (TSX VENTURE:MBI) today announces that it has become aware of a lawsuit by Signal Genetics, LLC and its subsidiary Respira Health LLC against MBI in the Supreme Court of the State of New York. MBI believes the claim is frivolous, vexatious and entirely without merit and intends to defend it vigorously.

A press release from Signal Genetics relating to the matter can be found here: http://www.businesswire.com/news/home/20110211006297/en/Signal-Genetics-Announces-Med-Biogene-Charged-Breach.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit www.medbiogene.com.

Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, that with respect to the timing, completion and/or results of clinical trials or studies, future profits, future product revenues, future operations and plans, the completion and use of proceeds from financings and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

Contact Information: Med BioGene Inc.
Erinn B. Broshko
Chief Executive Officer
(604) 827-4505
ebroshko@medbiogene.com
www.medbiogene.com